A First-in-Human, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of Gene Therapy With TTX-381 for the Ocular Manifestations Associated With Neuronal Ceroid Lipofuscinosis Type 2 (CLN2) Disease

NCT05791864 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
RECRUITING
Status
16
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Tern Therapeutics, LLC